RT @DrMHofman: 3rd line Rx with Lu-177 PSMA Theranostics: PSMA>50% decline in 44% versus 22% for conventional Rx: need prospective data but…
RT @DrMHofman: 3rd line Rx with Lu-177 PSMA Theranostics: PSMA>50% decline in 44% versus 22% for conventional Rx: need prospective data but…
RT @DrMHofman: 3rd line Rx with Lu-177 PSMA Theranostics: PSMA>50% decline in 44% versus 22% for conventional Rx: need prospective data but…
RT @DrMHofman: 3rd line Rx with Lu-177 PSMA Theranostics: PSMA>50% decline in 44% versus 22% for conventional Rx: need prospective data but…
RT @DrMHofman: 3rd line Rx with Lu-177 PSMA Theranostics: PSMA>50% decline in 44% versus 22% for conventional Rx: need prospective data but…
RT @DrMHofman: 3rd line Rx with Lu-177 PSMA Theranostics: PSMA>50% decline in 44% versus 22% for conventional Rx: need prospective data but…
RT @DrMHofman: 3rd line Rx with Lu-177 PSMA Theranostics: PSMA>50% decline in 44% versus 22% for conventional Rx: need prospective data but…
RT @DrMHofman: 3rd line Rx with Lu-177 PSMA Theranostics: PSMA>50% decline in 44% versus 22% for conventional Rx: need prospective data but…
RT @DrMHofman: 3rd line Rx with Lu-177 PSMA Theranostics: PSMA>50% decline in 44% versus 22% for conventional Rx: need prospective data but…
RT @DrMHofman: 3rd line Rx with Lu-177 PSMA Theranostics: PSMA>50% decline in 44% versus 22% for conventional Rx: need prospective data but…
RT @DrMHofman: 3rd line Rx with Lu-177 PSMA Theranostics: PSMA>50% decline in 44% versus 22% for conventional Rx: need prospective data but…
RT @DrMHofman: 3rd line Rx with Lu-177 PSMA Theranostics: PSMA>50% decline in 44% versus 22% for conventional Rx: need prospective data but…
RT @DrMHofman: 3rd line Rx with Lu-177 PSMA Theranostics: PSMA>50% decline in 44% versus 22% for conventional Rx: need prospective data but…
3rd line Rx with Lu-177 PSMA Theranostics: PSMA>50% decline in 44% versus 22% for conventional Rx: need prospective data but this is very encouraging. https://t.co/YE6BARpUDn https://t.co/CGzVELGCJa
Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. - PubMed - NCBI https://t.co/KSfc7bV5sw
Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. https://t.co/bPpJlCEoLD #News #Cancer https://t.co/KmNGFoQXq6